Global Custom Market Research Reports Provider Company

phone

Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review

  • Published Date: 04 Apr 2018
  • Number of Pages: 46
  • Category: Pharmaceuticals
  • Country: United States of America
Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at hematologic malignancies, and other tumors. The co-stimulatory antibodies harness human bodys natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. Heat Biologics off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It has subsidiaries in the US, Germany, and Australia. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc Key Recent Developments

Feb 28,2018: Heat Biologics Reports Fiscal Year 2017 Financial Results
Feb 28,2018: Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards
Nov 13,2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update
Nov 11,2017: Heat Biologics Presents Follow-up Data on its ComPACT T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 06,2017: Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData




Section 1 - About the Company 6
Heat Biologics Inc - Key Facts 6
Heat Biologics Inc - Key Employees 7
Heat Biologics Inc - Key Employee Biographies 8
Heat Biologics Inc - Major Products and Services 9
Heat Biologics Inc - History 10
Heat Biologics Inc - Company Statement 11
Heat Biologics Inc - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 Company Analysis 14
Company Overview 14
Heat Biologics Inc - Business Description 14
R&D Overview 14
Heat Biologics Inc - Corporate Strategy 16
Heat Biologics Inc - SWOT Analysis 17
SWOT Analysis - Overview 17
Heat Biologics Inc - Strengths 17
Heat Biologics Inc - Weaknesses 18
Heat Biologics Inc - Opportunities 19
Heat Biologics Inc - Threats 20
Heat Biologics Inc - Key Competitors 21
Section 3 Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 Companys Lifesciences Financial Deals and Alliances 28
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Heat Biologics Inc, Recent Deals Summary 30
Section 5 Companys Recent Developments 31
Feb 28, 2018: Heat Biologics Reports Fiscal Year 2017 Financial Results 31
Feb 28, 2018: Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards 32
Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 33
Nov 11, 2017: Heat Biologics Presents Follow-up Data on its ComPACT T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 34
Nov 06, 2017: Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 35
Oct 30, 2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its $15.2 Million CPRIT Grant Award 36
Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 37
Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 38
Jul 03, 2017: Heat Biologics Appoints Damien Hallet as Vice President of CMC Development 39
May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 40
Section 6 Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46

List Of Tables

List of Tables
Heat Biologics Inc, Key Facts 6
Heat Biologics Inc, Key Employees 7
Heat Biologics Inc, Key Employee Biographies 8
Heat Biologics Inc, Major Products and Services 9
Heat Biologics Inc, History 10
Heat Biologics Inc, Subsidiaries 13
Heat Biologics Inc, Key Competitors 21
Heat Biologics Inc, Ratios based on current share price 22
Heat Biologics Inc, Annual Ratios 23
Heat Biologics Inc, Annual Ratios (Cont...1) 24
Heat Biologics Inc, Interim Ratios 26
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Heat Biologics Inc, Recent Deals Summary 30
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45

The commercial combined heat and power (CHP) market is increasing modestly with an expected compound annual growth rate (CAGR) of 5.2% from 2017 through 2022. The market is segmented on

View Report

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review,

View Report

Report Heat Interchanger-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Heat Interchanger industry, standing on the readers perspective, delivering detailed market data and penetrating insights.

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports